Hamad Medical Corporation Awards QAR 32 Million Drug Supply Contract to Doha Drug Store

In a notable procurement move for Qatar’s healthcare sector, Hamad Medical Corporation (HMC) has awarded a direct agreement contract to Doha Drug Store for the supply of ZN-TRIKAFTA, a specialised pharmaceutical used in advanced respiratory treatment.

The contract, valued at QAR 32.05 million, was officially awarded on 20 November 2025 following a structured two-envelope evaluation process.

Contract Overview

The procurement was issued under Tender No. 6851/2025 and covers the supply of ZN-TRIKAFTA, a combination therapy widely used in the treatment of cystic fibrosis.

The medication package includes:

• Elexacaftor 100 mg

• Tezacaftor 50 mg

• Ivacaftor 75 mg (orange cap-shaped tablets)

• Ivacaftor 150 mg (blue cap-shaped tablets)

Each set is supplied in packs of 84 tablets, reflecting the drug’s high clinical value and specialised handling requirements.

The tender was conducted under a direct agreement procurement model, typically reserved for medicines that require specific authorisations, controlled supply chains, and proven clinical reliability.

Winning Bidder: Doha Drug Store

Doha Drug Store, registered under Commercial Registration No. 14993 \ 9039, was the only bidder to meet both the technical and financial requirements of the tender.

The company’s proposal, valued at QAR 32,052,787.20, was approved in full, confirming it as the contract’s final awarded value. Doha Drug Store also recorded a local value ratio of 13.29%, supporting Qatar’s broader strategy to encourage domestic participation within the pharmaceutical supply chain.

Importance of the Contract

The award highlights HMC’s commitment to ensuring uninterrupted access to advanced and life-saving medications for patients across Qatar. ZN-TRIKAFTA plays a critical role in managing complex respiratory conditions, particularly cystic fibrosis, where consistent treatment availability is essential to patient outcomes.

This procurement aligns with national healthcare objectives focused on drug security, treatment continuity, and system resilience.

For Doha Drug Store, the contract further reinforces its position as a trusted pharmaceutical distributor in Qatar, with a strong track record in supplying branded therapies and managing specialised medical logistics.

Technical and Financial Evaluation Process

The tender followed a two-envelope system, under which technical compliance was assessed before opening the financial proposal. Doha Drug Store successfully passed both evaluation stages, leading to the financial opening and official award on 20 November 2025.

This method ensures clinical suitability while maintaining financial transparency and procurement discipline.

Conclusion

With the contract now awarded, HMC and Doha Drug Store are expected to move forward with coordination of logistics and delivery schedules to ensure the timely distribution of ZN-TRIKAFTA across Qatar’s healthcare system.

The agreement strengthens Qatar’s pharmaceutical supply chain and reflects the country’s ongoing focus on high-quality, patient-centric healthcare procurement.

Latest Government Tenders and Contract Awards in Qatar - QatarTenders

• QatarTenders - Your trusted source for latest government tenders, RFPs, RFQs, and contract awards in Qatar

•  Stay updated with the latest public procurement opportunities and tender notices in Qatar at QatarTenders

•  Find all Qatar government tenders, eProcurement updates, and contract award notices on QatarTenders

• Explore live tenders, bids, and procurement opportunities in Qatar with QatarTenders - The QatarTenders portal

• QatarTenders brings you verified tenders, procurement news, and contract awards from Qatar

#QatarProcurement #ContractAward #TenderResults #HamadMedicalCorporation #DohaDrugStore #PharmaceuticalSupplyQatar #GovernmentContracts #HealthcareProcurement #AwardedTendersQatar #ZNTRIKAFTASupply